273216-16-3Relevant academic research and scientific papers
Solid phase synthesis of selective caspase-3 peptide inhibitors
Grimm, Erich L.,Roy, Bruno,Aspiotis, Renee,Bayly, Christopher I.,Nicholson, Donald W.,Rasper, Dita M.,Renaud, Johanne,Roy, Sophie,Tam, John,Tawa, Paul,Vaillancourt, John P.,Xanthoudakis, Steven,Zamboni, Robert J.
, p. 845 - 851 (2004)
A robust method for the solid phase synthesis of a series of selective caspase-3 peptide inhibitors is described. The inhibitors can be obtained after cleavage from the solid support without further purification.
Nicotinyl aspartyl ketones as inhibitors of caspase-3
Isabel, Elise,Black, W. Cameron,Bayly, Christopher I.,Grimm, Erich L.,Janes, Marc K.,McKay, Daniel J.,Nicholson, Donald W.,Rasper, Dita M.,Renaud, Johanne,Roy, Sophie,Tam, John,Thornberry, Nancy A.,Vaillancourt, John P.,Xanthoudakis, Steven,Zamboni, Robert
, p. 2137 - 2140 (2007/10/03)
Caspase-3 is a cysteinyl protease that mediates apoptotic cell death. Its inhibition may have an important impact in the treatment of several degenerative diseases. Since P1 aspartic acid is a required element of recognition for this enzyme, a
Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
-
, (2008/06/13)
The invention encompasses the novel class of compounds represented by formula I, which are caspase-3 inhibitors. The invention also encompasses certain pharmaceutical compositions for treatment of caspase-3 mediated diseases comprising compounds of formula I.
